Thermo Fisher Scientific Inc. (NYSE:TMO) Position Trimmed by Boston Financial Mangement LLC

Boston Financial Mangement LLC cut its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 19,879 shares of the medical research company’s stock after selling 157 shares during the period. Boston Financial Mangement LLC’s holdings in Thermo Fisher Scientific were worth $10,342,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of TMO. Mcdaniel Terry & Co. boosted its stake in Thermo Fisher Scientific by 1.8% in the fourth quarter. Mcdaniel Terry & Co. now owns 30,240 shares of the medical research company’s stock valued at $15,732,000 after acquiring an additional 540 shares during the period. Corps Capital Advisors LLC bought a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $1,148,000. Private Wealth Partners LLC boosted its position in shares of Thermo Fisher Scientific by 5.3% during the fourth quarter. Private Wealth Partners LLC now owns 63,203 shares of the medical research company’s stock worth $32,880,000 after buying an additional 3,197 shares during the period. Bryn Mawr Capital Management LLC increased its position in Thermo Fisher Scientific by 214.6% in the 4th quarter. Bryn Mawr Capital Management LLC now owns 35,183 shares of the medical research company’s stock valued at $18,303,000 after acquiring an additional 24,001 shares during the period. Finally, Financial Perspectives Inc boosted its position in Thermo Fisher Scientific by 119.6% during the 4th quarter. Financial Perspectives Inc now owns 459 shares of the medical research company’s stock worth $239,000 after acquiring an additional 250 shares during the period. Institutional investors own 89.23% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Wells Fargo & Company lifted their price objective on shares of Thermo Fisher Scientific from $660.00 to $680.00 and gave the company an “overweight” rating in a research note on Friday, January 31st. Royal Bank of Canada lowered their target price on Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. Evercore ISI reduced their price objective on shares of Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. StockNews.com upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Tuesday, January 14th. Finally, Sanford C. Bernstein upgraded shares of Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 target price for the company in a report on Friday, January 10th. Four analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Thermo Fisher Scientific has an average rating of “Moderate Buy” and an average price target of $658.00.

Insider Buying and Selling

In other news, CFO Stephen Williamson sold 9,825 shares of the stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the transaction, the chief financial officer now owns 27,296 shares of the company’s stock, valued at approximately $15,984,264.64. This represents a 26.47 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $175,677.00. Following the completion of the sale, the executive vice president now owns 16,363 shares of the company’s stock, valued at approximately $9,582,009.17. This trade represents a 1.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 20,125 shares of company stock worth $11,231,699. Insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Stock Performance

TMO stock opened at $531.41 on Thursday. The stock has a market cap of $203.26 billion, a P/E ratio of 32.15, a P/E/G ratio of 2.91 and a beta of 0.77. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The firm has a 50 day simple moving average of $548.10 and a 200 day simple moving average of $568.36. Thermo Fisher Scientific Inc. has a 52 week low of $493.30 and a 52 week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Friday, March 14th will be paid a $0.43 dividend. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a dividend yield of 0.32%. Thermo Fisher Scientific’s payout ratio is presently 9.44%.

Thermo Fisher Scientific announced that its board has initiated a stock buyback program on Friday, November 15th that permits the company to buyback $4.00 billion in shares. This buyback authorization permits the medical research company to repurchase up to 2% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s management believes its shares are undervalued.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.